EpiBone
New York, US · Founded 2013 · Delaware corporation · 22 employees on LinkedIn · 7 known investors
EpiBone engineers bone tissue from stem cells for regenerative medicine and clinical reconstruction, serving patients requiring bone grafts or craniofacial repair. The company translates tissue engineering research into therapeutic products for orthopedic and surgical applications.
Founders & leadership
EpiBone was founded in 2013 by Nina Tandon, Sarindr Bhumiratana, and Gordana Vunjak-Novakovic.
NT
Nina TandonCo-Founder, CEO
SB
Sarindr BhumiratanaCo-Founder
GV
Gordana Vunjak-NovakovicCo-founder
EH
Elma HawkinsNamed on SEC filing
Board
RL
Investors · 7
Reported raises · per SEC filings
Form D private placements$47.8M disclosed across 4 rounds · 2020–2025
▶$4.3MraisedOct 2025 · 131 investors · OtherRule 506(b)
▶$4.3MraisedOct 2025 · 131 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Robert LangerDirector
- Gordana Vunjak-NovakovicDirector
- Nina TandonExecutive Officer, Director
- Sarindr BhumiratanaExecutive Officer, Director
- David ZhuDirector
- Offering amount
- $4.3M
- Amount sold
- $4.3M
- First sale
- Sep 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$18.5MraisedDec 2022 · 51 investors · OtherRule 506(b)
▶$18.5MraisedDec 2022 · 51 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Nina TandonExecutive Officer, Director, Promoter
- Elma HawkinsDirector
- Robert LangerDirector
- Gordana Vunjak-NovakovicDirector
- Sarindr BhumiratanaExecutive Officer, Director
- David ZhuDirector
- Offering amount
- $36.8M
- Amount sold
- $18.5M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$750KraisedFeb 2021 · 4 investors · OtherRule 506(b)
▶$750KraisedFeb 2021 · 4 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Nina TandonExecutive Officer, Director, Promoter
- Sarindr BhumiratanaExecutive Officer, Director
- Gordana Vunjak-NovakovicDirector
- Elma HawkinsDirector
- Robert LangerDirector
- Offering amount
- $5M
- Amount sold
- $750K
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$24.3MraisedFeb 2020 · 140 investors · OtherRule 506(b)
▶$24.3MraisedFeb 2020 · 140 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Elma HawkinsDirector
- Sarindr BhumiratanaExecutive Officer, Director
- Nina TandonExecutive Officer, Director, Promoter
- Gordana Vunjak-NovakovicDirector
- Offering amount
- $26.6M
- Amount sold
- $24.3M
- First sale
- Jan 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapEpion Therapeutics</a> (Copy)6 shared keywordsEpion Therapeutics is developing EpiSmart, a minimally-invasive corneal cross-linking system to treat keratoconus and corneal ectasia without disrupting the epithelium. The treatment targets patients with ectatic corneal disease as an early-intervention standard of care.
Epi Biologics4 shared keywordsEpibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.
Biotechtv3 shared keywordsBiotechTV is a media outlet producing video shows, event coverage, and news focused on the biotech and healthcare sectors, including topics like venture funding, oncology conferences, and drug development. Its programming covers industry events, CEO interviews, science spotlights, and AI news for a biotech and life sciences audience.
Companies competing with EpiBone for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| Department of DefenseDefense Health Program | Phase II | 2018 | $999.9K |
| Department of DefenseDefense Health Program | Phase I | 2017 | $149K |
| U.S. ArmyArmy | Phase I | 2017 | $99.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2015 | $999.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $149.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does EpiBone do?
- EpiBone engineers bone tissue from stem cells for regenerative medicine and clinical reconstruction, serving patients requiring bone grafts or craniofacial repair. The company translates tissue engineering research into therapeutic products for orthopedic and surgical applications.
- Who founded EpiBone?
- EpiBone was founded by Nina Tandon, Sarindr Bhumiratana, Gordana Vunjak-Novakovic in 2013.
- Who are EpiBone's investors?
- EpiBone's investors include Beresford Ventures, EMV Capital, Hackensack Meridian Health Bear's Den, Kendall Capital Partners, Plum Alley Investments, Tachyon Ventures, Tech Council Ventures.
- How much funding has EpiBone raised?
- EpiBone has disclosed $47.8M raised across 4 rounds.
- Where is EpiBone headquartered?
- EpiBone is headquartered in New York, US.